Forepont Capital Partners

Okeiro is a technology company specializing in AI-driven solutions for chronic disease and transplant care. It develops predictive algorithms, specifically for kidney transplantation, to assess long-term organ failure risk and personalize treatment plans. The platform aims to enhance clinical decision-making, streamline workflows, and improve patient outcomes by enabling early detection and monitoring.

AlterDiag is a medical diagnostics company that specializes in the development and commercialization of innovative lateral flow immunochromatographic tests. These tests, which use single-chain variable fragment antibodies, are designed to provide rapid, cost-effective, and user-friendly diagnostic solutions for healthcare professionals and patients alike. AlterDiag's products are intended for use in healthcare centers and at home, enabling swift and personalized medical responses.

GPN Vaccines is a biotechnology company developing a vaccine for Streptococcus pneumoniae bacteria. Its vaccine aims to prevent life-threatening pneumonia, bacteremia, meningitis, and otitis media.

GPN Vaccines is a biotechnology company developing a vaccine for Streptococcus pneumoniae bacteria. Its vaccine aims to prevent life-threatening pneumonia, bacteremia, meningitis, and otitis media.

Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.

Mobius Biomedical plans to bring unprecedented efficiencies to the development and manufacturing of biologics and biosimilars, and reduce their cost by over 90% at commercial scale. The Company has developed new design, new process and new equipment to drastically reduce the capex, opex and facility footprint of manufacturing plants while maintaining the purity, throughput and efficiency at commercial scale.

Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.

GPN Vaccines is a biotechnology company developing a vaccine for Streptococcus pneumoniae bacteria. Its vaccine aims to prevent life-threatening pneumonia, bacteremia, meningitis, and otitis media.

BayBridgeDigital Group LLC, established in 2017, is a New York-based digital advisory and consulting firm with additional offices in Paris and Tel Aviv. It specializes in digital transformation services, including e-commerce, digital marketing, mobile solutions, data analytics, AI, Salesforce integration, and software development. The company serves clients from various industries such as retail, energy, healthcare, and finance, helping them achieve business value through digital solutions. BayBridgeDigital's approach combines design-led strategies with expertise in the Salesforce ecosystem to deliver exceptional results and accelerate digital transformations.